LAVA Therapeutics NV financial data

Location
Utrecht
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 684 %
Debt-to-equity 207 %
Return On Equity -108 %
Return On Assets -35.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.3M shares
Common Stock, Shares, Outstanding 26.3M shares
Entity Public Float 29M USD
Common Stock, Value, Issued 3.72M USD
Weighted Average Number of Shares Outstanding, Basic 26.9M shares +0.2%
Weighted Average Number of Shares Outstanding, Diluted 26.9M shares +0.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.99M USD
Research and Development Expense 19.7M USD -72.9%
General and Administrative Expense 14.6M USD +73.4%
Costs and Expenses 34.3M USD -33.4%
Operating Income (Loss) -29.4M USD +33.4%
Nonoperating Income (Expense) 6.85M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.5M USD +41.3%
Income Tax Expense (Benefit) 682K USD -93.8%
Net Income (Loss) Attributable to Parent -23.2M USD +41.7%
Earnings Per Share, Basic 0 USD/shares +41.3%
Earnings Per Share, Diluted 0 USD/shares +41.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.7M USD
Other Assets, Current 2.1M USD
Assets, Current 51.9M USD
Property, Plant and Equipment, Net 43K USD
Operating Lease, Right-of-Use Asset 353K USD
Other Assets, Noncurrent 10K USD
Assets 51.9M USD
Accounts Payable, Current 1.7M USD
Employee-related Liabilities, Current 1.11M USD
Liabilities, Current 4.23M USD
Contract with Customer, Liability, Noncurrent 35M USD
Operating Lease, Liability, Noncurrent 6K USD
Liabilities 39.2M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -9.78M USD
Retained Earnings (Accumulated Deficit) -194M USD
Stockholders' Equity Attributable to Parent 12.7M USD -61.6%
Liabilities and Equity 51.9M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.6M USD -1281%
Net Cash Provided by (Used in) Financing Activities 8K USD
Net Cash Provided by (Used in) Investing Activities 15.2M USD +2084%
Common Stock, Shares Authorized 90M shares
Common Stock, Shares, Issued 26.3M shares
Common Stock, Par or Stated Value Per Share 0.14 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 49.7M USD +84.2%
Deferred Tax Assets, Valuation Allowance 41.4M USD +11.7%
Deferred Tax Assets, Gross 41.5M USD +11.4%
Operating Lease, Liability 395K USD
Payments to Acquire Property, Plant, and Equipment 23K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.3M USD +27.9%
Lessee, Operating Lease, Liability, to be Paid 425K USD
Property, Plant and Equipment, Gross 3.01M USD -9.86%
Operating Lease, Liability, Current 306K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 77K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 343K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3K USD
Deferred Tax Assets, Operating Loss Carryforwards 28M USD +51.7%
Preferred Stock, Shares Authorized 45M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2K USD
Additional Paid in Capital 213M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 107K USD -25.7%
Deferred Tax Assets, Net of Valuation Allowance 138K USD -37.3%